SPY304.32+1.35 0.45%
DIA254.29-0.06 -0.02%
IXIC9,489.87+120.88 1.29%

Surface Oncology To Present Results From First-In-Human Phase 1 Study Of SRF231 at ASCO

Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that data from the Phase 1 study of SRF231,

Benzinga · 05/14/2020 11:35

Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that data from the Phase 1 study of SRF231, a fully human, high-affinity anti-CD47 antibody, will be presented at the American Society of Clinical Oncology (ASCO) 2020 Annual Meeting, to be held virtually May 29-31.

A summary is provided below; the full poster will be placed on Surface Oncology’s website following the presentation.

Presentation Type: e-poster (Abstract: 3064 / Poster: 128)
Title: Results of a first-in-human Phase 1 study of SRF231, a fully human, high-affinity anti-CD47 antibody
Lead Author: Amita Patnaik
Session: Developmental Therapeutics - Immunotherapy

In 2018, Surface Oncology deprioritized the SRF231 clinical program and is concluding its Phase 1 study.